title: Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib.
abstract: Proteasomes degrade the majority of proteins in mammalian cells, are involved in the regulation of multiple physiological functions, and are established targets of anticancer drugs. The proteasome has three types of active sites. Chymotrypsin-like sites are the most important for protein breakdown and have long been considered the only suitable targets for antineoplastic drugs; however, our recent work demonstrated that inhibitors of caspase-like sites sensitize malignant cells to inhibitors of the chymotrypsin-like sites. Here, we describe the development of specific cell-permeable inhibitors and an activity-based probe of the trypsin-like sites. These compounds selectively sensitize multiple myeloma cells to inhibitors of the chymotrypsin-like sites, including antimyeloma agents bortezomib and carfilzomib. Thus, trypsin-like sites are cotargets for anticancers drugs. Together with inhibitors of chymotrypsin- and caspase-like sites developed earlier, we provide the scientific community with a complete set of tools to separately modulate proteasome active sites in living cells.
authors: Department of Pharmacology and Toxicology, Dartmouth Medical School, Dartmouth College, Lebanon, NH 03756, USA.
authors: Anne C
authors: AC
authors: Mirabella
authors: Alexandre A
authors: AA
authors: Pletnev
authors: Sondra L
authors: SL
authors: Downey
authors: Bogdan I
authors: BI
authors: Florea
authors: Tamer B
authors: TB
authors: Shabaneh
authors: Matthew
authors: M
authors: Britton
authors: Martijn
authors: M
authors: Verdoes
authors: Dmitri V
authors: DV
authors: Filippov
authors: Herman S
authors: HS
authors: Overkleeft
authors: Alexei F
authors: AF
authors: Kisselev
references: Chembiochem. 2008 Jul 21;9(11):1735-8
references: 18600815
references: Angew Chem Int Ed Engl. 2003 Aug 11;42(31):3626-9
references: 12916032
references: Methods Enzymol. 1994;244:500-11
references: 7845228
references: J Med Chem. 2009 May 14;52(9):3028-38
references: 19348473
references: Biochim Biophys Acta. 2004 Nov 29;1695(1-3):33-44
references: 15571807
references: Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10403-8
references: 10468620
references: Adv Immunol. 2002;80:1-70
references: 12078479
references: Chem Biol. 2001 Sep;8(9):913-29
references: 11564559
references: Drug Discov Today. 1999 Feb;4(2):63-71
references: 10234158
references: Chem Biol. 2006 Nov;13(11):1217-26
references: 17114003
references: Cancer Cell. 2005 Nov;8(5):407-19
references: 16286248
references: Chem Biol. 1999 Apr;6(4):197-204
references: 10099130
references: Chem Biol. 2010 Aug 27;17(8):795-801
references: 20797608
references: Cancer Res. 2007 Jul 1;67(13):6383-91
references: 17616698
references: Anal Biochem. 2009 Apr 15;387(2):294-302
references: 19454251
references: J Biol Chem. 2006 Mar 31;281(13):8582-90
references: 16455650
references: Cancer Res. 2005 Sep 1;65(17):7896-901
references: 16140960
references: Biochemistry. 1998 May 26;37(21):7792-800
references: 9601040
references: J Clin Oncol. 2005 Sep 1;23(25):6107-16
references: 16135477
references: EMBO J. 2001 May 15;20(10):2357-66
references: 11350924
references: Chem Biol. 2001 Aug;8(8):739-58
references: 11514224
references: Chem Biol. 2009 Dec 24;16(12):1278-89
references: 20064438
references: Chem Biol. 2002 May;9(5):655-62
references: 12031672
references: Chem Biol. 2008 May;15(5):419-21
references: 18482693
references: Cancer Cell. 2004 May;5(5):417-21
references: 15144949
references: Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):2967-72
references: 11248015
references: J Med Chem. 2005 Jul 28;48(15):5038-42
references: 16033282
references: Blood. 2008 Mar 1;111(5):2765-75
references: 18057228
references: Methods Enzymol. 2005;398:364-78
references: 16275343
references: Nat Methods. 2005 May;2(5):357-62
references: 15846363
references: Cancer Res. 2010 Mar 1;70(5):1970-80
references: 20160034
references: Chem Biol. 2001 Dec;8(12):1131-41
references: 11755392
references: Crit Rev Oncol Hematol. 2008 Oct;68(1):12-28
references: 18396408
references: Immunogenetics. 1995;41(4):178-228
references: 7890324
references: J Med Chem. 2010 Mar 11;53(5):2319-23
references: 20131905
references: Clin Cancer Res. 2009 Nov 15;15(22):7085-91
references: 19903785
references: J Biol Chem. 2010 Dec 17;285(51):40125-34
references: 20937826